RTEL1-TNFRSF6B

Across TCGA pan-cancer cohorts, RTEL1-TNFRSF6B Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RTEL1-TNFRSF6B data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher RTEL1-TNFRSF6B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTEL1-TNFRSF6B expression acts as an unfavorable survival marker.

UCS and SKCM are the cancer types where RTEL1-TNFRSF6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	IV	0.132	0.718	.002	12	view →
SKCM	DFS	Median	II,III,IV	0.297	0.692	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RTEL1-TNFRSF6B–UCS (DFS)

Open the UCS breakdown →